388MO Tumor budding, an important prognostic factor in stage III colon cancer patients treated with oxaliplatin-based chemotherapy
Debora Basile(University of Udine), Magali Svrcek(Centre Léon Bérard), Julien Taı̈eb(Hôpital Européen Georges-Pompidou), Jaafar Bennouna(Hôpital Foch), Jérôme Desrame(Hôpital Privé Jean Mermo), Clémence Toullec(Institut Sainte Catherine), Thierry André(Inserm), Serge Fratté(Université de technologie de belfort-montbéliard), Emile Jf(Université de Versailles Saint-Quentin-en-Yvelines), Christophe Louvet(Institute Mutualiste Montsouris), Alexandre Falcoz(Inserm), Chloé Broudin(Assistance Publique – Hôpitaux de Paris)
Cited by 0
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
|New England Journal of Medicine|2020|2.9k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k